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Head and neck squamous cell carcinoma (HNSCC)
ranks among the 10 most common cancers in the
world and has been thought to correlate highly with
environmental risk factors such as smoking, alcohol
drinking, betel nut chewing and human papilloma
virus infection.1 Among these risk factors, the betel nut
chewing habit is the most regionally specific to South
East Asian countries such as Thailand, Philippines,
Papua New Guinea, and Taiwan. The mechanism that
underlies the carcinogenesis in relation to betel nut
chewing is complex, involving both physical and chem-
ical etiologies. Repeated long-term exposure to betel
nut-related carcinogens resulted in persistent damage
of oral mucosa and is reflected in the high prevalence
of buccal cancer in young male patients in Taiwan,2
which in turn generates social and economic burdens.
In recent years, the development of anti-epidermal
growth factor receptor (EGFR) monoclonal antibody
opened up a new era of therapy for head and neck
cancer both in combination with radiotherapy and
palliative chemotherapy.3,4 In the treatment of recur-
rent/metastatic head and neck cancer, a phase III ran-
domized controlled trial showed a significant survival
benefit in the group treated with platinum-based
chemotherapy plus cetuximab combination versus the
control group treated with platinum-based chemo-
therapy alone (10.1 months vs. 7.4 months for overall
survival; 5.6 months vs. 3.3 months for progression-
free survival), an unprecedented result over the past 30
years.4 However, it is interesting to note that response
to anti-EGFR treatment still cannot be predicted. The
potential mechanisms of resistance to EGFR-targeted
therapy are being studied, including EGFR overex-
pression and amplification, as well as k-ras mutation.5–7
The question of interest is whether or not anti-EGFR
treatment exerts its effect on patients with long-term
exposure to betel nut-related carcinogens, which may
be involved in a complex of carcinogenic pathways. In
a study published in the June 2010 issue of the Journal
of the Chinese Medical Association, Chang et al8 retro-
spectively analyzed recurrent/metastatic HNSCC pa-
tients who received cetuximab-based therapy alone or
in combination with other chemotherapy. In the study,
60% of patients had a betel nut chewing habit, 92%
were male, and 20% of patients had buccal cancer. The
results showed a high overall response rate and dis-
ease control rate in both the first-line chemotherapy
group and the cisplatin-failure therapy group (54% vs.
20% in overall response rate; 62% vs. 50% in disease
control rate) with acceptable toxicities [grade III/IV
infection/fever (23% in the first-line group, 50% in the
cisplatin-failure group) and neutropenia (23% in the
first-line group, 25% in the cisplatin-failure group)].
This report reached an encouraging conclusion that
cetuximab-based therapy is an effective and safe treat-
ment choice for recurrent/metastatic HNSCC in an
area in which betel nut chewing is popular. A more
in-depth response analysis revealed a higher complete
remission rate in the first-line therapy group with the
addition of taxane as well as in the cisplatin treatment
failure group with the addition of chemotherapy. More-
over, the survival analysis showed a better response to
treatment in patients with 1st recurrent/metastatic dis-
ease and without betel nut chewing habit. The weak-
ness of the study was that the sample population was
small, rendering it difficult to draw a definite conclu-
sion on the subject matter. However, the results did
imply poor prognosis in the subgroup of patients who
fail to respond to cisplatin treatment and who have a
habit of chewing betel nuts. The results also implied
that aggressive combination treatment with anti-EGFR
agents and chemotherapy may increase treatment res-
ponse and result in better prognosis in suitable patients.
However, selection bias was inevitable in such a retro-
spectively conducted study for patients accepting
cetuximab-based therapies. Further prospective, large
randomized trials using cetuximab combination ther-
apy in this specific group of patients who have long-
term exposure to betel nut-related carcinogens are
warranted.
The gene mutations and associated changes in phe-
notype are usually complex in correlation with environ-
mental carcinogens and cancer. In betel nut related
carcinogens, EGFR overexpression9 and gene copy
number amplification10 have been found to be associ-
ated with carcinogenesis. In the near future, patient
selection for anti-EGFR based therapy, especially in areas
with a high prevalence of betel nut chewing, holds
promise for improving treatment outcomes in recur-
rent/metastatic head and neck cancer.
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